Schlimok G
II. Medizinischen Klinik, Hämatologie/Onkologie, Klinikum Augsburg.
MMW Fortschr Med. 2001 Jun 21;143(25):24-8.
Among the various immunotherapeutic approaches, monoclonal antibodies in particular have acquired clinical relevance. In patients with non-Hodgkin's lymphoma and in breast cancer it has been shown that antibody therapy and chemotherapy are not rival forms of treatment, but that the best clinical response is obtained with a combination of the two. Cellular immunotherapy with lymphokine-activated killer cells, tumor-infiltrating lymphocytes, allogeneic T-cells and dendritic cells is still in the experimental stage. This is also true of therapeutic vaccination with tumor antigens. The best clinical results of treatment with antibodies or immunotherapy may be expected in patients with minimal residual disease.
在各种免疫治疗方法中，单克隆抗体尤其具有临床意义。在非霍奇金淋巴瘤患者和乳腺癌患者中，已表明抗体疗法和化疗并非相互竞争的治疗形式，而是两者联合使用可获得最佳临床反应。使用淋巴因子激活的杀伤细胞、肿瘤浸润淋巴细胞、同种异体T细胞和树突状细胞进行细胞免疫治疗仍处于实验阶段。肿瘤抗原治疗性疫苗接种也是如此。对于微小残留病患者，使用抗体或免疫疗法治疗有望获得最佳临床结果。
